Differentiated product
Nimodipine
Oral solution · Subarachnoid haemorrhage
Product data
- Dosage form
- Oral solution
- Dosage-form group
- Oral liquid
- Therapeutic area
- Subarachnoid haemorrhage
- Reference product
- Oral solution 3 mg/mL, 6 mg/mL
- KMS approach
- Competitive generic therapy approach
- Status
- Under development
- Development stage
- 2 of 5 · Development
- Portfolio
- Differentiated product
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23